Global Melanoma Cell & Gene Therapy Market to Witness Substantial Growth with a CAGR of 17.5% by 2031 – ResearchAndMarkets.com
Global Melanoma Cell & Gene Therapy Market to Witness Substantial Growth with a CAGR of 17.5% by 2031 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Melanoma Cell and Gene Therapy Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast to 2031” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The global melanoma cell and gene therapy market is projected to experience substantial growth by 2031.
The report provides an assessment of the disease epidemiology and a 10-year patient-based forecast (PBF) across the 8MM (8 major markets) for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class.
Key Market Highlights:
- Cell & Gene Therapies in Melanoma Pipeline: Cell & gene therapies (CGTs) constitute a modest proportion of the overall melanoma pipeline but show promising potential. Gene therapies dominate the CGT pipeline, with several agents in different phases of clinical development.
- Competition and Market Projections: CGT agents are expected to face high levels of competition in the melanoma market. The melanoma CGT market across the 8MM is projected to reach $801 million in 2031, while overall melanoma market sales across 15 major markets (15MM) are expected to reach peak sales of $7.6 billion in 2031.
- Addressing Unmet Needs: CGT therapies are likely to address some unmet needs in the melanoma patient population, although patients currently have relatively effective first-line and second-line treatment options.
Report Scope:
The report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies, and early- to late-clinical stage pipeline products with a launch date assessment by the 8MM market.
Reasons to Buy:
- Obtain cell & gene therapy sales forecasts across multiple regions.
- Gain insight into promising early-stage approaches in melanoma treatment.
- Understand the clinical stage pipeline and the anticipated breakdown between autologous and allogeneic cell therapies.
- Identify future players and catalysts in the melanoma cell and gene therapy market.
A selection of Companies mentioned in this report includes:
- Iovance Biotherapeutics
- Replimune
- Wuhan Binhui Biopharmaceutical
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/s5tnh0
Source: GlobalData
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900